<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340046</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091016</ELocationID><Abstract><AbstractText>Bullous pemphigoid (BP) is the most common autoimmune bullous disease, whose main autoantigens are hemidesmosomal components BP180 and BP230. Although recent studies found no association between COVID-19 vaccines and BP, since mass vaccinations started, more than 90 vaccine-associated BP cases have been reported. To find an agreement among real-life clinical observations and recent epidemiologic data, we further investigated this topic. A total of 64 patients with BP onset in 2021 were demographically, clinically, and serologically characterized: 14 (21.9%) vaccine-associated patients (VA) developed BP within 5 weeks from the first/second vaccine dose. VA and vaccine-non-associated (VNA) patients had similar demographics and clinical and immunological characteristics. Noteworthy, the monthly distribution of BP onset during mass vaccinations paralleled vaccine administration to the elderly in the same catchment area. Additionally, in 2021, BP onsets in April-May and June-July significantly increased (<i>p</i> = 0.004) and declined (<i>p</i> = 0.027), respectively, compared to the three years before vaccination campaigns (2018-2020). Interestingly, VA and VNA patients showed statistically significant differences in the use of inhalers and diuretics. Our findings suggest that the COVID-19 vaccine may constitute an accelerating factor that, together with other triggering factors, could act in genetically predisposed individuals with possible sub-clinical autoreactivity against BP antigens, slightly accelerating BP onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pira</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7172-619X</Identifier><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariotti</LastName><ForeName>Feliciana</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7004-5031</Identifier><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dermatology Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didona</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rare Diseases Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaglione</LastName><ForeName>Giovanni Luca</ForeName><Initials>GL</Initials><Identifier Source="ORCID">0000-0001-5622-7843</Identifier><AffiliationInfo><Affiliation>Bioinformatic Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panebianco</LastName><ForeName>Annarita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Direction, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abeni</LastName><ForeName>Damiano</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Zenzo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6106-599X</Identifier><AffiliationInfo><Affiliation>Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, 00167 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>12367807</GrantID><Agency>Ministero della Salute</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">autoimmune bullous disease</Keyword><Keyword MajorTopicYN="N">bullous pemphigoid</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340046</ArticleId><ArticleId IdType="pmc">PMC11436231</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091016</ArticleId><ArticleId IdType="pii">vaccines12091016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borradori L., Van Beek N., Feliciani C., Tedbirt B., Antiga E., Bergman R., Böckle B.C., Caproni M., Caux F., Chandran N.S., et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) J. Eur. Acad. Dermatol. Venereol. 2022;36:1689–1704. doi: 10.1111/jdv.18220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18220</ArticleId><ArticleId IdType="pubmed">35766904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt E., della Torre R., Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Immunol. Allergy Clin. N. Am. 2012;32:217–232. doi: 10.1016/j.iac.2012.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.iac.2012.04.002</ArticleId><ArticleId IdType="pubmed">22560135</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro F., Fania L., Sinagra J.L.M., Salemme A., Di Zenzo G. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules. 2020;10:1432. doi: 10.3390/biom10101432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10101432</ArticleId><ArticleId IdType="pmc">PMC7600534</ArticleId><ArticleId IdType="pubmed">33050407</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheyden M.J., Bilgic A., Murrell D.F. A Systematic Review of Drug-Induced Pemphigoid. Acta Derm. Venereol. 2020;100:adv00224. doi: 10.2340/00015555-3457.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-3457</ArticleId><ArticleId IdType="pmc">PMC9207627</ArticleId><ArticleId IdType="pubmed">32176310</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto Superiore di Sanità  EpiCentro—Epidemiology for Public Health.  [(accessed on 27 August 2024)].  Available online:  https://www.epicentro.iss.it/en/vaccines/covid-19-vaccination-plan.</Citation></Reference><Reference><Citation>Ricci F., Fania L., Paradisi A., Di Lella G., Pallotta S., Sobrino L., Panebianco A., Annessi G., Abeni D. Delayed melanoma diagnosis in the COVID-19 era: Increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J. Eur. Acad. Dermatol. Venereol. 2020;34:e778–e779. doi: 10.1111/jdv.16874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.16874</ArticleId><ArticleId IdType="pmc">PMC7436601</ArticleId><ArticleId IdType="pubmed">32780876</ArticleId></ArticleIdList></Reference><Reference><Citation>Moro F., Mariotti F., Pira A., Sobrino L., Pallotta S., Panebianco A., Di Zenzo G. The impact of COVID-19 pandemic on the number of first diagnosis and follow-up visits of patients affected by pemphigus, bullous pemphigoid, scleroderma, psoriasis and vitiligo: A single-centre experience. J. Eur. Acad. Dermatol. Venereol. 2024;38:e453–e455. doi: 10.1111/jdv.19885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.19885</ArticleId><ArticleId IdType="pubmed">38400642</ArticleId></ArticleIdList></Reference><Reference><Citation>Maronese C.A., Caproni M., Moltrasio C., Genovese G., Vezzoli P., Sena P., Previtali G., Cozzani E., Gasparini G., Parodi A., et al. Bullous Pemphigoid Associated with COVID-19 Vaccines: An Italian Multicentre Study. Front. Med. 2022;9:841506. doi: 10.3389/fmed.2022.841506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.841506</ArticleId><ArticleId IdType="pmc">PMC8918943</ArticleId><ArticleId IdType="pubmed">35295599</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Liu X., Chen X., Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun. Rev. 2023;22:103340. doi: 10.1016/j.autrev.2023.103340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103340</ArticleId><ArticleId IdType="pmc">PMC10108562</ArticleId><ArticleId IdType="pubmed">37075917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xu Z., Wang P., Li X.M., Shuai Z.W., Ye D.Q., Pan H.F. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386–401. doi: 10.1111/imm.13443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13443</ArticleId><ArticleId IdType="pubmed">34957554</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Ouyang X., Zhang D., Wang X., Wu L., Yu S., Tan Y., Li W., Li C. Alopecia areata following COVID-19 vaccine: A systematic review. Eur. J. Med. Res. 2024;29:356. doi: 10.1186/s40001-024-01956-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-024-01956-8</ArticleId><ArticleId IdType="pmc">PMC11225413</ArticleId><ArticleId IdType="pubmed">38970130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesqué D., Lopez-Trujillo E., Marcantonio O., Giménez-Arnau A.M., Pujol R.M. New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: Two sides of the same coin? J. Eur. Acad. Dermatol. Venereol. 2022;36:e80–e81. doi: 10.1111/jdv.17690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.17690</ArticleId><ArticleId IdType="pubmed">34547146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P.C., Huang I.H., Wang C.Y., Chi C.C. New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review. Vaccines. 2024;12:465. doi: 10.3390/vaccines12050465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12050465</ArticleId><ArticleId IdType="pmc">PMC11125893</ArticleId><ArticleId IdType="pubmed">38793716</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A., Nemati M., Jafarzadeh S., Nozari P., Mortazavi S.M.J. Thyroid dysfunction following vaccination with COVID-19 vaccines: A basic review of the preliminary evidence. J. Endocrinol. Investig. 2022;45:1835–1863. doi: 10.1007/s40618-022-01786-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-022-01786-7</ArticleId><ArticleId IdType="pmc">PMC8960081</ArticleId><ArticleId IdType="pubmed">35347651</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymans S., Cooper L.T. Myocarditis after COVID-19 mRNA vaccination: Clinical observations and potential mechanisms. Nat. Rev. Cardiol. 2022;19:75–77. doi: 10.1038/s41569-021-00662-w. Erratum in Nat. Rev. Cardiol. 2023, 20, 575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00662-w</ArticleId><ArticleId IdType="pmc">PMC8656440</ArticleId><ArticleId IdType="pubmed">34887571</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.J., Cines D.B., Gernsheimer T., Kessler C., Michel M., Tarantino M.D., Semple J.W., Arnold D.M., Godeau B., Lambert M.P., et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am. J. Hematol. 2021;96:534–537. doi: 10.1002/ajh.26132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26132</ArticleId><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha J., Park S., Kang H., Kyung T., Kim N., Kim D.K., Kim H., Bae K., Song M.C., Lee K.J., et al. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: A prospective surveillance study. Sci. Rep. 2023;13:3773. doi: 10.1038/s41598-023-30940-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-30940-1</ArticleId><ArticleId IdType="pmc">PMC9989583</ArticleId><ArticleId IdType="pubmed">36882454</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahra V., Makandura M., Anthony D.D., Mattar M. A Case Series on the COVID-19 Vaccines and Possible Immune-Related Adverse Events: A New Challenge for the Rheumatologists. Cureus. 2022;14:e29660. doi: 10.7759/cureus.29660.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.29660</ArticleId><ArticleId IdType="pmc">PMC9612893</ArticleId><ArticleId IdType="pubmed">36321010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagy I., Zeller L., Raviv Y., Porges T., Bieber A., Abu-Shakra M. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: A case series and literature review. Rheumatol. Int. 2022;42:2261–2266. doi: 10.1007/s00296-022-05203-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05203-3</ArticleId><ArticleId IdType="pmc">PMC9468534</ArticleId><ArticleId IdType="pubmed">36098769</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Torres V., Gutiérrez Á., Valdenebro M., Ortega A., Cítores M.J., Montero E. Catastrophic antiphospholipid syndrome triggered by mRNA COVID-19 vaccine. Clin. Exp. Rheumatol. 2022;40:1054–1055. doi: 10.55563/clinexprheumatol/s3sbgu.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/s3sbgu</ArticleId><ArticleId IdType="pubmed">34874824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharabi A., Shiber S., Molad Y. Adult-onset Still’s disease following mRNA COVID-19 vaccination. Clin. Immunol. 2021;233:108878. doi: 10.1016/j.clim.2021.108878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108878</ArticleId><ArticleId IdType="pmc">PMC8575550</ArticleId><ArticleId IdType="pubmed">34763089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagini F., Carrel L., Fallet B., Gachoud D., Ribi C., Monti M. Behçet’s-like adverse event or inaugural Behçet’s disease after SARS-CoV-2 mRNA-1273 vaccination? Rheumatology. 2022;61:e112–e113. doi: 10.1093/rheumatology/keab751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab751</ArticleId><ArticleId IdType="pmc">PMC8522430</ArticleId><ArticleId IdType="pubmed">34617989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bril F., Al Diffalha S., Dean M., Fettig D.M. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? J. Hepatol. 2021;75:222–224. doi: 10.1016/j.jhep.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8056822</ArticleId><ArticleId IdType="pubmed">33862041</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydoğan B.İ., Ünlütürk U., Cesur M. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination. Endocrine. 2022;78:42–46. doi: 10.1007/s12020-022-03130-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-022-03130-8</ArticleId><ArticleId IdType="pmc">PMC9282628</ArticleId><ArticleId IdType="pubmed">35809159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A., Jafarzadeh S., Pardehshenas M., Nemati M., Mortazavi S.M.J. Development and exacerbation of autoimmune hemolytic anemia following COVID-19 vaccination: A systematic review. Int. J. Lab. Hematol. 2023;45:145–155. doi: 10.1111/ijlh.13978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13978</ArticleId><ArticleId IdType="pmc">PMC9874780</ArticleId><ArticleId IdType="pubmed">36208056</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang J., Xu J., Xia H., Wang Y., Zhang C., Chen W., Zhang H., Liu Q., Zhu R., et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov. 2021;7:99. doi: 10.1038/s41421-021-00329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00329-3</ArticleId><ArticleId IdType="pmc">PMC8546144</ArticleId><ArticleId IdType="pubmed">34697287</ArticleId></ArticleIdList></Reference><Reference><Citation>Biering S.B., Gomes de Sousa F.T., Tjang L.V., Pahmeier F., Zhu C., Ruan R., Blanc S.F., Patel T.S., Worthington C.M., Glasner D.R., et al. SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling. Nat. Commun. 2022;13:7630. doi: 10.1038/s41467-022-34910-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34910-5</ArticleId><ArticleId IdType="pmc">PMC9734751</ArticleId><ArticleId IdType="pubmed">36494335</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocamora-Reverte L., Melzer F.L., Würzner R., Weinberger B. The Complex Role of Regulatory T Cells in Immunity and Aging. Front. Immunol. 2021;11:616949. doi: 10.3389/fimmu.2020.616949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.616949</ArticleId><ArticleId IdType="pmc">PMC7873351</ArticleId><ArticleId IdType="pubmed">33584708</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H., Li Q., Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun. Rev. 2020;19:102661. doi: 10.1016/j.autrev.2020.102661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102661</ArticleId><ArticleId IdType="pubmed">32942041</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghari F., Asghary A., Majidi Zolbanin N., Faraji F., Jafari R. Immunosenescence and Inflammaging in COVID-19. Viral Immunol. 2023;36:579–592. doi: 10.1089/vim.2023.0045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2023.0045</ArticleId><ArticleId IdType="pubmed">37797216</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-Pedrero M.Á., Jansen J.M., Blume C., Stanislawski N., Jonczyk R., Molle A., Hernandez M.G., Kaiser F.K., Jung K., Osterhaus A.D.M.E., et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat. Aging. 2022;2:896–905. doi: 10.1038/s43587-022-00292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00292-y</ArticleId><ArticleId IdType="pmc">PMC10154205</ArticleId><ArticleId IdType="pubmed">37118289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Dong C., Han Y., Gu Z., Sun C. Immunosenescence, aging and successful aging. Front. Immunol. 2022;13:942796. doi: 10.3389/fimmu.2022.942796.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.942796</ArticleId><ArticleId IdType="pmc">PMC9379926</ArticleId><ArticleId IdType="pubmed">35983061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pira A., Sinagra J.L.M., Moro F., Mariotti F., Di Zenzo G. Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine. Front. Med. 2023;10:1112823. doi: 10.3389/fmed.2023.1112823.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1112823</ArticleId><ArticleId IdType="pmc">PMC9893122</ArticleId><ArticleId IdType="pubmed">36744126</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri B., Betterle C., Zanoni G. Vaccinations and Autoimmune Diseases. Vaccines. 2021;9:815. doi: 10.3390/vaccines9080815.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080815</ArticleId><ArticleId IdType="pmc">PMC8402446</ArticleId><ArticleId IdType="pubmed">34451940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasperkiewicz M., Bednarek M., Tukaj S. Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React with Pemphigus or Pemphigoid Autoantigens. Front. Med. 2021;8:807711. doi: 10.3389/fmed.2021.807711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.807711</ArticleId><ArticleId IdType="pmc">PMC8720918</ArticleId><ArticleId IdType="pubmed">34988105</ArticleId></ArticleIdList></Reference><Reference><Citation>Birabaharan M., Kaelber D.C., Orme C.M., Paravar T., Karris M.Y. Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination. Br. J. Dermatol. 2022;187:271–273. doi: 10.1111/bjd.21240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.21240</ArticleId><ArticleId IdType="pmc">PMC9111668</ArticleId><ArticleId IdType="pubmed">35279833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministero della Salute  GitHub.  [(accessed on 22 July 2024)]; Available online:  https://github.com/italia/covid19-opendata-vaccini#descrizione-repository.</Citation></Reference><Reference><Citation>Venning V.A., Wojnarowska F. Induced bullous pemphigoid. Br. J. Dermatol. 1995;132:831–832. doi: 10.1111/j.1365-2133.1995.tb00739.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.1995.tb00739.x</ArticleId><ArticleId IdType="pubmed">7772498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti F., Grosso F., Terracina M., Ruffelli M., Cordiali-Fei P., Sera F., Zambruno G., Mastrogiacomo A., Di Zenzo G. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br. J. Dermatol. 2004;151:1004–1010. doi: 10.1111/j.1365-2133.2004.06245.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2004.06245.x</ArticleId><ArticleId IdType="pubmed">15541078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammon W.R., Briggaman R.A., Inman A.O., 3rd, Queen L.L., Wheeler C.E. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J. Investig. Dermatol. 1984;82:139–144. doi: 10.1111/1523-1747.ep12259692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1523-1747.ep12259692</ArticleId><ArticleId IdType="pubmed">6363567</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsalu T., Vilo J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res. 2015;43:W566–W570. doi: 10.1093/nar/gkv468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv468</ArticleId><ArticleId IdType="pmc">PMC4489295</ArticleId><ArticleId IdType="pubmed">25969447</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell D.F.M., Daniel B.S., Joly P., Borradori L., Amagai M., Hashimoto T., Caux F., Marinovic B., Sinha A.A., Hertl M., et al. Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. J. Am. Acad. Dermatol. 2012;66:479–485. doi: 10.1016/j.jaad.2011.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2011.06.032</ArticleId><ArticleId IdType="pmc">PMC3883429</ArticleId><ArticleId IdType="pubmed">22056920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pira A., Moltrasio C., Abeni D., Corrà A., Marzano A.V., Caproni M., Di Zenzo G. Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study. Front. Med. 2023;10:1160672. doi: 10.3389/fmed.2023.1160672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1160672</ArticleId><ArticleId IdType="pmc">PMC10060545</ArticleId><ArticleId IdType="pubmed">37007791</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Astolto R., Quintarelli L., Corrà A., Caproni M., Fania L., Di Zenzo G., Didona B., Gasparini G., Cozzani E., Feliciani C. Environmental factors in autoimmune bullous diseases with a focus on seasonality: New insights. Dermatol. Rep. 2023;15:9641. doi: 10.4081/dr.2023.9641.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/dr.2023.9641</ArticleId><ArticleId IdType="pmc">PMC10518530</ArticleId><ArticleId IdType="pubmed">37753233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kridin K., Ludwig R.J., Tzur Bitan D., Cohen A.D. A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study. Dermatology. 2021;237:921–928. doi: 10.1159/000512917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512917</ArticleId><ArticleId IdType="pubmed">33640889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kridin K., Hammers C.M., Ludwig R.J., Onn E., Schonmann Y., Abu-Elhija A., Tzur Bitan D., Schmidt E., Weinstein O., Cohen A.D. The Association of Bullous Pemphigoid with Atopic Dermatitis and Allergic Rhinitis—A Population-Based Study. Dermatitis. 2022;33:268–276. doi: 10.1097/DER.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DER.0000000000000792</ArticleId><ArticleId IdType="pubmed">34570736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.Q., Zhang J.Z. A Comparison for Type 2 Cytokines and Lesional Inflammatory Infiltrations in Bullous Pemphigoid and Atopic Dermatitis. Clin. Cosmet. Investig. Dermatol. 2022;15:2313–2321. doi: 10.2147/CCID.S376845.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CCID.S376845</ArticleId><ArticleId IdType="pmc">PMC9620838</ArticleId><ArticleId IdType="pubmed">36325102</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedlickova H., Racovska J., Niedermeier A., Feit J., Hertl M. Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus. Eur. J. Dermatol. 2008;18:534–538. doi: 10.1684/ejd.2008.0483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ejd.2008.0483</ArticleId><ArticleId IdType="pubmed">18693156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieland C.N., Comfere N.I., Gibson L.E., Weaver A.L., Krause P.K., Murray J.A. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol. 2010;146:21–25. doi: 10.1001/archdermatol.2009.331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archdermatol.2009.331</ArticleId><ArticleId IdType="pubmed">20083688</ArticleId></ArticleIdList></Reference><Reference><Citation>Feliciani C., Caldarola G., Kneisel A., Podstawa E., Pfütze M., Pfützner W., Hertl M. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br. J. Dermatol. 2009;161:306–312. doi: 10.1111/j.1365-2133.2009.09266.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2009.09266.x</ArticleId><ArticleId IdType="pubmed">19485996</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beek N., Dohse A., Riechert F., Krull V., Recke A., Zillikens D., Schmidt E. Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited. Br. J. Dermatol. 2014;170:943–947. doi: 10.1111/bjd.12739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.12739</ArticleId><ArticleId IdType="pubmed">24734947</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer J.M., Lamberts A., Pas H.H., Jonkman M.F. Significantly higher prevalence of circulating bullous pemphigoid-specific IgG autoantibodies in elderly patients with a nonbullous skin disorder. Br. J. Dermatol. 2015;173:1274–1276. doi: 10.1111/bjd.13874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.13874</ArticleId><ArticleId IdType="pubmed">25912001</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nicolas-Ruanes B., Ballester-Martinez A., Garcia-Mouronte E., Berna-Rico E., Azcarraga-Llobet C., Fernandez-Guarino M. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid. Int. J. Mol. Sci. 2023;24:16786. doi: 10.3390/ijms242316786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242316786</ArticleId><ArticleId IdType="pmc">PMC10706090</ArticleId><ArticleId IdType="pubmed">38069109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostan E., Yel B., Akdogan N., Gokoz O. New-onset bullous pemphigoid after inactivated COVID-19 vaccine: Synergistic effect of the COVID-19 vaccine and vildagliptin. Dermatol. Ther. 2022;35:e15241. doi: 10.1111/dth.15241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15241</ArticleId><ArticleId IdType="pubmed">34854184</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo R., Gasparini G., Cozzani E., D’Agostino F., Parodi A. Absolving COVID-19 vaccination of autoimmune bullous disease onset. Front. Immunol. 2022;13:834316. doi: 10.3389/fimmu.2022.834316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.834316</ArticleId><ArticleId IdType="pmc">PMC8895245</ArticleId><ArticleId IdType="pubmed">35251024</ArticleId></ArticleIdList></Reference><Reference><Citation>Maronese C.A., Di Zenzo G., Genovese G., Barei F., Monestier A., Pira A., Moltrasio C., Marzano A.V. Reply to “New-onset bullous pemphigoid after inactivated COVID-19 vaccine: Synergistic effect of the COVID-19 vaccine and vildagliptin”. Dermatol. Ther. 2022;35:e15496. doi: 10.1111/dth.15496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15496</ArticleId><ArticleId IdType="pmc">PMC9111836</ArticleId><ArticleId IdType="pubmed">35388592</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>